-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNTech Said 2026 Is Poised To Be Catalyst-Rich Year With Continued Late-stage Pipeline Progress

Benzinga·01/12/2026 11:48:02
Listen to the news
  • Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end
  • Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product oncology company
  • Financial strength with €17.2 billion in cash and cash equivalents plus security investments1, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation